Analyzing of Production Conditions of 89Zr in the Particle Accelerator
Abstract
Nowadays 89Zr is outstanding PET radionuclide with its physical half-life (t1/2 ~ 78 hours), useful decay specifications and so that it is suitable for antibody-based immuno-PET. Relatively oscillated positrons' low decay energies supply to take high-resolution. 89Zr-labeled radiopharmaceuticals, especially as 89Zr-labeled antibodies applications are getting increase day by day.
In this study, calculations about production of 89Zr were
done and used (p,n) reaction of 89Y target system. For this Q-value, Threshold
Energy, Minimum Coulomb Barrier Energy of the reaction were calculated then the
cross-sections of this reaction were found using Empire3.2/MALTA code. After
determining the irradiation calculations, the bombardment performed. The
irradiation was performed in Ankara Sarayköy Nuclear Research and Training
Center, proton accelerator. The cyclotron is IBA type Cyclone-30. Then
separation part was done with Dowex resine system. After separation 89Zr from
the irradiated target system, radioactive 89Zr was obtained purely.
Keywords
89Zr,Cyclone-30,Empire3.2/MALTA,Radionuclide,Dowex,PET Radionuclides
References
- Adonai N., Nguyen K.N., Walsh J., Iyer M., Toyokuni T., Phelps M.E., McCarthy T., McCarthy D.W. and Gambhir S.S., Ex-vivo Cell Labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for Imaging Cell Trafficking in Mice with Positron Emission Tomography, Proc. Natl. Acad. Sci. U.S.A., 5 (2002), 99(5), 3030-3035.
- Aerts H.J.W.L., Dubois L., Perk L., Vermaelen P., van Dongen G.A.M.S., Wouters B.G. and Lambin P., Disparity Between in-vivo EGFR Expression and 89Zr Labeled Cetuximab Uptake Assessed with PET, J. Nucl. Med., 50 (2009), 123–131.
- Alfuraih A., Alzimami K., Ma A.K. and Alghamdi A, Optimization of 89Zr Production Using Monte Carlo Simulations, J. Radioanal. Nucl. Chem., 296 (2013), 1025–1029.
- Avila-Rodriguez M.A., Selwyn R.G., Converse A.K. and Nickles R.J., 86Y and 89Zr as PET Imaging Surrogates for 90Y: A Comparative Study, Proceedings of Ninth Mexican Symposium on Medical Physics, (2006) pp 45–47.
- Becker W., Emmrich F., Horneff G., Burmester G., Seiler F., Schwarz A., Kalden J. and Wolf F., Imaging Rheumatoid Arthritis Specifically with Technetium-99m CD4-specific (T-helper lymphocytes) Antibodies, Eur. J. Nucl. Med., 17, (1990), 156159.
- Borjesson P.K.E., Jauw Y.W.S., de Bree R., Roos J.C., Castelijns J., Leemans C.R., van Dongen G.AM.S. and Boellaard R., Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients, J. Nucl. Med., 50(11), (2009), 1828–1836.
- Borjesson P.K.E., Jauw Y.W.S., Boellaard R., de Bree R., Comans E.F.I., Roos J.C., Castelijns J.A., Vosjan M.J., Kummer J.A., Leemans C.R., Lammertma A.A. and van Dongen G.A., Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, 12 (2006), 2133-2140.
- Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., van Dongen G.A., Schröder C.P., Lub-de Hooge M.N. and de Vries E.G., Biodistribution of 89Zr-Trastuzumab and PET Imaging of HER2-Positive Lesions in Patients with Metastatic Breast Cancer, Clin. Pharmacol. Ther., 87 (2010), 586–592.
- Dijkers E.C.F., Kosterink J.G.W., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., de Jong J.R., de Vries E.G.E. and Lub-de Hooge M.N., Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, J. Nucl. Med., 50 (2009), 974–981.
- Disselhorst J.A., Brom M., Laverman P., Slump C.H., Boerman O.C., Oyen W.J.G., Gotthardt M. and Visser E.P., Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small Animal PET Scanner, J. Nucl. Med., 51 (2010), 610617.